Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics Q2 net loss narrows to $91.2 million from $208.5 million

Positive Impact 3 of 5 earnings Written later

CRISPR Therapeutics reported second quarter 2026 results, with total revenue of $10.2 million versus $0.9 million a year earlier and a net loss of $91.2 million, down from $208.5 million. The company stated CASGEVY generated $76 million in second quarter revenue and that the FDA approved CASGEVY for children 2 years and older, while cash and marketable securities totaled $2.36 billion at June 30, 2026.

Key points

  • Net loss was $91.2 million, or $0.94 per share, versus a net loss of $208.5 million, or $2.40 per share, in Q2 2025
  • Total revenue was $10.2 million versus $0.9 million a year earlier; the filing shows $10.0 million of collaboration revenue
  • Cash, cash equivalents and marketable securities were $2,364.4 million at June 30, 2026, including $585.4 million of net proceeds from convertible senior notes issued in March 2026
  • Acquired in-process R&D expense fell to $2.5 million from $96.3 million, which the company linked to the 2025 Sirius Agreement

The filing

CompanyCRISPR Therapeutics AG (CRSP)
Form8-K, current report
Filed with the SECAug 3, 2026, 4:24 PM ET
Accession number0001193125-26-330644

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.